Inventor · disambiguated record
Andrew Lawrence Feldhaus
Also filed as: FELDHAUS ANDREW · FELDHAUS ANDREW L · FELDHAUS ANDREW LAWRENCE
30 granted patents·13 pending applications·390 citations·filing 1994–2025
97Inventor score
Files withALDERBIO HOLDINGS LLC12ICOSAVAX INC6ZYMOGENETICS INC6TARGETED GENETICS CORP5ALDER BIOPHARMACEUTICALS INC3
Top patents by PatentIndex Score
43 records- 0196US9957321B2Anti-IL-6 antibodies for the treatment of oral mucositisALDERBIO HOLDINGS LLC·Filed 2015·Granted May 1, 2018·15 cites·18 claims
- 0296US9255154B2Anti-PCSK9 antibodies and use thereofALDERBIO HOLDINGS LLC·Filed 2013·Granted Feb 9, 2016·36 cites·20 claims
- 0395US9481725B2Antibodies to HGF and compositions containingALDERBIO HOLDINGS LLC·Filed 2014·Granted Nov 1, 2016·16 cites·11 claims
- 0495US6936466B2Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectorsTARGETED GENETICS CORP·Filed 2001·Granted Aug 30, 2005·47 cites·109 claims
- 0594US10100108B2Antibodies to HGF and compositions containingALDERBIO HOLDINGS LLC·Filed 2016·Granted Oct 16, 2018·6 cites·20 claims
- 0693US8992908B2Anti-IL-6 antibodies for the treatment of oral mucositisSMITH JEFFREY T L·Filed 2011·Granted Mar 31, 2015·14 cites·35 claims
- 0793US6902729B2Murine interferon-αZYMOGENETICS INC·Filed 2003·Granted Jun 7, 2005·27 cites·4 claims
- 0892US9783603B2Therapeutic use of antibodies to HGFALDERBIO HOLDINGS LLC·Filed 2015·Granted Oct 10, 2017·5 cites·14 claims
- 0992US9062104B2Therapeutic use of antibodies to HGFALDERBIO HOLDINGS LLC·Filed 2013·Granted Jun 23, 2015·10 cites·17 claims
- 1091US11427631B2Anti-ACTH antibodies and use thereofH LUNDBECK AS·Filed 2020·Granted Aug 30, 2022·2 cites·26 claims
- 1191US6312924B1Murine interferon-αZYMOGENETICS INC·Filed 2000·Granted Nov 6, 2001·19 cites·23 claims
- 1288US11117960B2Humanized anti-ACTH antibodies and use thereofALDERBIO HOLDINGS LLC·Filed 2019·Granted Sep 14, 2021·2 cites·26 claims
- 1386US10259885B2Anti-PCSK9 antibodies and use thereofALDERBIO HOLDINGS LLC·Filed 2015·Granted Apr 16, 2019·4 cites·21 claims
- 1486US6548056B2Murine interferon-αZYMOGENETICS INC·Filed 2001·Granted Apr 15, 2003·9 cites·7 claims
- 1586US6346415B1Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectorsTARGETED GENETICS CORP·Filed 1998·Granted Feb 12, 2002·40 cites·35 claims
- 1683US10544214B2Humanized anti-ACTH antibodies and use thereofALDER BIOPHARMACEUTICALS INC·Filed 2018·Granted Jan 28, 2020·2 cites·20 claims
- 1783US9732150B2Therapeutic use of antibodies to HGFALDERBIO HOLDINGS LLC·Filed 2014·Granted Aug 15, 2017·6 cites·17 claims
- 1882US12351627B2Anti-ACTH antibodies and use thereofH LUNDBECK AS·Filed 2022·Granted Jul 8, 2025·0 cites·13 claims
- 1981US10550180B2Anti-ACTH antibodies and use thereofALDERBIO HOLDINGS LLC·Filed 2017·Granted Feb 4, 2020·2 cites·8 claims
- 2081US10047157B2Humanized anti-ACTH antibodies and use thereofALDER BIOPHARMACEUTICALS INC·Filed 2015·Granted Aug 14, 2018·2 cites·11 claims
- 2179US9688754B2Anti-ACTH antibodies and use thereofALDER BIOPHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·2 cites·8 claims
- 2278US12428475B2Humanized anti-ACTH antibodies and use thereofH LUNDBECK AS·Filed 2021·Granted Sep 30, 2025·0 cites·30 claims
- 2378US6083751AChimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cellsTARGETED GENETICS CORP·Filed 1995·Granted Jul 4, 2000·56 cites·12 claims
- 2477US12343391B2Protein-based nanoparticle vaccine for metapneumovirusICOSAVAX INC·Filed 2023·Granted Jul 1, 2025·0 cites·35 claims
- 2577US6245529B1Testis-specific cystatin-like protein cystatin TZYMOGENETICS INC·Filed 2000·Granted Jun 12, 2001·4 cites·14 claims
- 2675US11806394B2Protein-based nanoparticle vaccine for metapneumovirusICOSAVAX INC·Filed 2023·Granted Nov 7, 2023·0 cites·30 claims
- 2772US5874556AHybrid genes for use in the production of TH -independent cytotoxic T cellsTARGETED GENETICS CORP·Filed 1994·Granted Feb 23, 1999·25 cites·18 claims
- 2871US2021332126A1Anti-il-6 antibodies for the treatment of oral mucositisVITAERIS INC·Filed 2021·Application pending·0 cites
- 2969US5759805ACD69 transcriptional regulatory elementsTARGETED GENETICS CORP AND IMM·Filed 1995·Granted Jun 2, 1998·26 cites·24 claims
- 3069US2025325651A1Protein-based nanoparticle vaccine for metapneumovirusICOSAVAX INC·Filed 2025·Application pending·0 cites
- 3166US2019023780A1Anti-il-6 antibodies for the treatment of oral mucositisALDERBIO HOLDINGS LLC·Filed 2018·Application pending·0 cites
- 3266US2025161436A1Multivalent vaccine for paramyxoviruses and uses thereofICOSAVAX INC·Filed 2024·Application pending·0 cites
- 3358US2019389968A1Anti-pcsk9 antibodies and use thereofALDERIBIO HOLDINGS LLC·Filed 2019·Application pending·0 cites
- 3458US2019085066A1Antibodies to hgf and compositions containingALDERBIO HOLDINGS LLC·Filed 2018·Application pending·0 cites
- 3556US2006019382A1Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectorsFELDHAUS ANDREW L·Filed 2005·Application pending·0 cites
- 3652US6235708B1Testis-specific cystatin-like protein cystatin TZYMOGENETICS INC·Filed 1999·Granted May 22, 2001·13 cites·10 claims
- 3747US2002192777A1Testis protein, Zsig86Filed 2001·Application pending·0 cites
- 3847US2005032700A1Adipocyte complement related protein zacrp12Filed 2004·Application pending·0 cites
- 3947US2005048615A1Adipocyte complement related protein zacrp11Filed 2004·Application pending·0 cites
- 4046US2002151492A1Testis specific proteinZYMOGENETICS INC·Filed 2001·Application pending·0 cites
- 4146US2025177513A1Rabies g protein and uses thereofICOSAVAX INC·Filed 2025·Application pending·0 cites
- 4238US2025222092A1Protein nanostructure vaccineICOSAVAX INC·Filed 2025·Application pending·0 cites
- 4332US6593124B1Hybrid genes for expression of stimulatory factors in activated T cellsTARGETED GENETICS CORP·Filed 1998·Granted Jul 15, 2003·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Andrew Lawrence Feldhaus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →